We are live on
!
Find out more
Acadia Pharmaceuticals
ACAD
ACAD
210 hedge funds and large institutions have $3.61B invested in Acadia Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 82 increasing their positions, 64 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
28% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 64
0.38% more ownership
Funds ownership: 96.25% → 96.63% (+0.38%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 36
1% less funds holding
Funds holding: 212 → 210 (-2)
19% less capital invested
Capital invested by funds: $4.44B → $3.61B (-$825M)
30% less call options, than puts
Call options by funds: $24.9M | Put options by funds: $35.6M
Holders
210
Holders Change
-2
Holders Change %
-0.94%
% of All Funds
4.76%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
36
Increased
82
Reduced
64
Closed
36
Calls
$24.9M
Puts
$35.6M
Net Calls
-$10.7M
Net Calls Change
+$16.6M
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$53.4M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$45M |
| 3 |
O
OrbiMed
New York
|
+$27.2M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$26.3M |
| 5 |
Morgan Stanley
New York
|
+$17.1M |
Top Sellers
| 1 |
SIG
Senator Investment Group
New York
|
-$54.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$40.7M |
| 3 |
EM
Elliott Management
New York
|
-$40M |
| 4 |
Goldman Sachs
New York
|
-$20.1M |
| 5 |
PC
PointState Capital
New York
|
-$11.5M |
